Yahoo
NasdaqCM - Nasdaq Real Time Price USD

SAB Biotherapeutics, Inc. (SABS)

3.7100 -0.0800 (-2.11%)
At close: August 31 at 4:00:00 PM EDT
3.7100 0.0000 (0.00%)
Pre-Market: 8:18:49 AM EDT
Trade SABS on Coinbase
Chart Range Bar
Loading chart for SABS
  • Previous Close 3.7900
  • Open 3.7600
  • Bid 3.8300 x 100
  • Ask 3.7200 x 100
  • Day's Range 3.6900 - 3.8000
  • 52 Week Range 1.8500 - 5.1500
  • Volume 201,143
  • Avg. Volume 668,830
  • Market Cap (intraday) 337.559M
  • Beta (5Y Monthly) 0.53
  • PE Ratio (TTM) 15.46
  • EPS (TTM) 0.2400
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.64

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

www.sab.bio

86

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SABS
0.80%
S&P 500 (^GSPC)
12.28%

1-Year Return

SABS
78.37%
S&P 500 (^GSPC)
18.98%

3-Year Return

SABS
48.47%
S&P 500 (^GSPC)
70.51%

5-Year Return

SABS
96.28%
S&P 500 (^GSPC)
69.95%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -22.49M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q2

FY26

-20M
0
20M
40M
0.0%

Analyst Insights

View More

Analyst Price Targets

6.00
11.64 Average
3.7100 Current
16.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/24/2026
Analyst Barclays
Rating Action Initiated
Rating Overweight
Price Action Announces
Price Target 13

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    356.67M

  • Enterprise Value

    259.17M

  • Trailing P/E

    16.33

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.66

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    64.16

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -33.46%

  • Return on Equity (ttm)

    -11.27%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -21.79M

  • Diluted EPS (ttm)

    0.2400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    102.63M

  • Total Debt/Equity (mrq)

    2.39%

  • Levered Free Cash Flow (ttm)

    -28.84M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

3.7100 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: